Osteoporosis Medications

Osteoporosis Medications and Raloxifene (Evista)

Raloxifene (Evista) is an osteoporosis medication approved for the prevention and treatment of postmenopausal osteoporosis. It is from a class of medications called selective estrogen receptor modulators (SERMs) that appear to prevent bone loss in the spine, hip, and elsewhere in the body.
Raloxifene has beneficial effects on bone mass and bone turnover, and can reduce the risk of vertebral fractures.
While side effects are not common with raloxifene, those reported include hot flashes and blood clots in the veins, the latter of which is also associated with estrogen therapy. Additional research studies on raloxifene will continue for several more years.

Osteoporosis Medications and Calcitonin (Miacalcin, Fortical)

Calcitonin is a naturally occurring hormone involved in calcium regulation and bone metabolism. In women who are at least 5 years past menopause, calcitonin slows bone loss, increases spinal bone density, and (according to anecdotal reports) relieves the pain associated with bone fractures. Calcitonin reduces the risk of spinal fractures and may reduce the risk of hip fractures as well. Studies on fracture reduction are ongoing. Calcitonin is currently available as an injection or nasal spray.
While it does not affect other organs or systems in the body, injectable calcitonin may cause an allergic reaction and unpleasant side effects, including flushing of the face and hands, frequent urination, nausea, and skin rash. The most common side effect reported with the nasal spray form of calcitonin is a runny nose.

Osteoporosis Medications and Teriparatide (Forteo)

Teriparatide (Forteo) is an injectable form of human parathyroid hormone. It is an osteoporosis medication approved for postmenopausal women and for men with osteoporosis who are at high risk for having a fracture. Teriparatide stimulates new bone formation in both the spine and the hip. It also reduces the risk of vertebral and nonvertebral fractures in postmenopausal women.
In men, teriparatide reduces the risk of vertebral fractures. However, it is not known whether teriparatide reduces the risk of nonvertebral fractures.
Side effects include nausea, dizziness, and leg cramps. Teriparatide is approved for use for up to 24 months.
Osteoporosis: Muscle Strengthening

Osteoporosis Medications-Overview

Terms of Use
Advertise with Us
Contact Us
About eMedTV
Privacy Policy
Copyright © 2006-2019 Clinaero, Inc.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click Terms of Use for more information.